218 related articles for article (PubMed ID: 24795564)
1. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.
Hannig G; Tchernychev B; Kurtz CB; Bryant AP; Currie MG; Silos-Santiago I
Front Mol Neurosci; 2014; 7():31. PubMed ID: 24795564
[TBL] [Abstract][Full Text] [Related]
2. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
Silos-Santiago I; Hannig G; Eutamene H; Ustinova EE; Bernier SG; Ge P; Graul C; Jacobson S; Jin H; Liong E; Kessler MM; Reza T; Rivers S; Shea C; Tchernychev B; Bryant AP; Kurtz CB; Bueno L; Pezzone MA; Currie MG
Pain; 2013 Sep; 154(9):1820-1830. PubMed ID: 23748116
[TBL] [Abstract][Full Text] [Related]
4. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
[TBL] [Abstract][Full Text] [Related]
5. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA
Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587
[TBL] [Abstract][Full Text] [Related]
6. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.
Corsetti M; Tack J
United European Gastroenterol J; 2013 Feb; 1(1):7-20. PubMed ID: 24917937
[TBL] [Abstract][Full Text] [Related]
7. Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain.
Brierley SM; Grundy L; Castro J; Harrington AM; Hannig G; Camilleri M
Trends Pharmacol Sci; 2022 Feb; 43(2):110-122. PubMed ID: 34865885
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical profile of linaclotide (Linzess
Keto Y; Kosako M
Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
[TBL] [Abstract][Full Text] [Related]
9. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
[TBL] [Abstract][Full Text] [Related]
10. Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents.
Feng B; Kiyatkin ME; La JH; Ge P; Solinga R; Silos-Santiago I; Gebhart GF
J Neurosci; 2013 Jun; 33(23):9831-9. PubMed ID: 23739979
[TBL] [Abstract][Full Text] [Related]
11. Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology.
Uranga JA; Castro M; Abalo R
Curr Med Chem; 2018; 25(16):1879-1908. PubMed ID: 29210639
[TBL] [Abstract][Full Text] [Related]
12. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
Layer P; Stanghellini V
Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
[TBL] [Abstract][Full Text] [Related]
13. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
Eutamene H; Bradesi S; Larauche M; Theodorou V; Beaufrand C; Ohning G; Fioramonti J; Cohen M; Bryant AP; Kurtz C; Currie MG; Mayer EA; Bueno L
Neurogastroenterol Motil; 2010 Mar; 22(3):312-e84. PubMed ID: 19706070
[TBL] [Abstract][Full Text] [Related]
14. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
Sedky AA; Magdy Y
Life Sci; 2020 Sep; 256():117960. PubMed ID: 32534033
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
[TBL] [Abstract][Full Text] [Related]
18. Guanylin and uroguanylin: a promising nexus in intestinal electrolyte and fluid homeostasis.
Samanta S; Chaudhuri AG
J Physiol Pharmacol; 2021 Oct; 72(5):. PubMed ID: 35158329
[TBL] [Abstract][Full Text] [Related]
19. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
McCormack PL
Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
[TBL] [Abstract][Full Text] [Related]
20. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.
Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS
Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
